Apoptosis in epithelial ovarian tumours. Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax)

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 130, Issue 1, 2007, Pages 121-128

  de la Torre, F Javier ^a,b   García, Angel ^b   Gil Moreno, Antonio ^b   Planaguma, Jesus ^b   Reventos, Jaume ^b   Cajal, Santiago Ramón y ^b   Xercavins, Jordi ^b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Apoptosis; Bax; bcl 2; Epithelial ovarian tumours; p53; Prognosis factors

Indexed keywords

EOSIN; HEMATOXYLIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER STAGING; CLEAR CELL CARCINOMA; DISEASE FREE INTERVAL; ENDOMETRIOID CARCINOMA; ENZYME ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NICK END LABELING; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 33845478760     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.11.048     Document Type: Article

References (46)

1. Canistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2516-2529
2. NIH Consensus Conference. Ovarian cancer. Screening, treatment and follow-up. JAMA 1995;273:491-7.
3. Bromley B., Goodman H., and Benacerraf B.R. Comparison between sonographic morphology and doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 83 (1994) 434-437
4. Swenerton K.D., Hislop T.G., Spinelli J., Leriche J.C., Yang N., and Boyes A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65 (1985) 264-270
5. Nguyen H.N., Averette H.E., Hoskins W., Sevin B.U., Peñalver M., and Steren A. National survey of ovarian carcinoma, VI: critical assessment of current international federation of gynecology and obstetrics staging system. Cancer 72 (1993) 3007-3011
6. Tropé C., and Kaern J. DNA ploidy in epithelial ovarian cancer: a new independent prognosis factor?. Gynecol Oncol 53 (1994) 1-4
7. Pejovic T. Genetic changes in ovarian cancer. Ann Med 27 (1995) 73-78
8. Scambia G., Benedetti-Pacini P., and Ferrandina G. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72 (1995) 361-366
9. Matias-GuiuX, and Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch 433 (1998) 103-111
10. Kerr J.F., Wyllie A.H., and Curie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 (1972) 13-20
11. Afford S., Randhawa S., and Apoptosis. J Clin Pathol Mol Pathol 53 (2000) 55-63
12. Sjöström J., and Bergh J. How apoptosis is regulated, and what goes wrong in cancer. BMJ 322 (2001) 1538-1539
13. Antonsson B., and Martinou J.C. The Bcl-2 protein family. Exp Cell Res 256 (2000) 50-57
14. Hockenberry D., Nuñez G., and Milliman C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-386
15. Krajewski S., Krajewska M., Shabaik A., Miyashita T., Wang H.-G., and Reed J.C. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 145 (1994) 1323-1333
16. Yin C., Knudson C.M., Korsmeyer S.J., and Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385 (1997) 637-640
17. Lozano G., and Elledge S.J. Cancer: p53 sends nucleotides to repair DNA. Nature 404 (2000) 24-25
18. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (1999) 483-487
19. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
20. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., and Stark G.R. The p53 network. J Biol Chem 273 (1998) 1-4
21. Soini Y., Päkko P., and Lehto V.P. Histopathological evaluation of apoptosis in cancer. Am J Pathol 153 (1998) 1041-1049
22. Selva D.M., Tirado O.M., Torán N., Suárez-Quian C.A., Reventos J., and Munell F. Meiotic arrest and germ cell apoptosis in androgen-binding protein transgenic mice. Endocrinology 141 (2000) 1168-1177
23. Pajak T., ClarK G.H., Sargent D.J., McShane L.H., and Hammon E.H. Statistical issues in tumor marker studies. Arch Pathol Lab Med 124 (2000) 1011-1015
24. Cardon L.R., and Bell J.I. Association study design for complex disease. Nat Genet 3 (2001) 91-99
25. Green D.R. Apoptotic pathways: the roads to win. Cell 94 (1998) 695-698
26. Schneider P., and Tschopp J. Apoptosis induced by death receptor. Pharm Acta Helv 74 (2000) 281-286
27. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
28. Harrison D.J. Counting apoptosis-why and how?. J Clin Pathol Mol Pathol 49 (1996) 245-246
29. Kiyozuka Y., Akamatsu T., Singh A., Ichiyoshi T., Senzaki H., and Tsubura A. Optimal prefixation of cells to demonstrate apoptosis by the TUNEL method. Acta Cytol 43 (1999) 393-399
30. Langlois N.E., Lamb J., Eremin O., and Heis S.D. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis and immunohistochemical demonstrations of p53, c-myc and bcl-2 protein products. J Pathol 182 (1997) 392-397
31. Wyllie A.H. Apoptosis and carcinogenesis. Eur J Cell Biol 73 (1997) 189-197
32. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
33. Wallace-Brodeur R.R., and Lowe S. Clinical implications of p53 mutations. Cell Mol Life Sci 55 (1999) 64-75
34. Shanin M.S., Hughes J.H., Sood A.K., and Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89 (2000) 2006-2017
35. Chan W.Y., Cheung K.K., Schorge J.O., et al. Bcl-2 and p53 protein expression, apoptosis and p53 mutation in human epithelial ovarian cancers. Am J Pathol 156 (2000) 409-417
36. Logullo A.F., Pereira de Moura R., Nonogaki S., Kowalski L.P., Nagai M.A., and Simpson A.J. A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. Diagn Mol Pathol 9 (2000) 35-40
37. Levine A. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
38. Loeffler M., and Kroemer G. The mitochondria in cell death control: certainties and incognita. Exp Cell Res 256 (2000) 19-26
39. Lipponen P.K., Aaltomaa S., Kosma V.M., and Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30 (1994) 2068-2073
40. Pezzella F., Turley H., and Kuzu I. Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329 (1993) 690-694
41. Witty J.P., Jensen R.A., and Johnson A.L. Expression and localization of Bcl-2 related protein in human ovarian cancers. Anti-cancer Res 18 (1998) 1223-1230
42. Geisler J.P., Geisler H.E., Miller G.A., Wiemann M.C., Zhou Z., and Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 77 (2000) 278-282
43. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
44. Marone M., Scambia G., Mozzeti S., et al. bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 4 (1998) 517-524
45. Diebold J., Baretton G., Felchner M., et al. Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinoma. Am J Clin Pathol 105 (1996) 341-349
46. Ono K., Tanaka T., Tsunoda T., et al. Identification by c-DNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60 (2000) 5007-5011